Safety and Effectiveness of 100 mg/kg/day Deferiprone in Patients with Thalassemia Major
Deferiprone at a dose of 75 mg/kg/day is not sufficiently effective to maintain iron stores at a level which has been considered safe in all patients with iron overload. Our main aim was to determine the safety of long-term therapy with high-dose (100 mg/kg/day) deferiprone. A secondary aim was to d...
Saved in:
| Main Author: | Taher, A. (author) |
|---|---|
| Other Authors: | Sheikh-Taha, M. (author), Sharara, A. (author), Inati, A. (author), Koussa, S. (author), Dhillon, A.P. (author), Hoffbrand, A.V. (author) |
| Format: | article |
| Published: |
2005
|
| Online Access: | http://hdl.handle.net/10725/3922 http://dx.doi.org/10.1159/000087888 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.karger.com/Article/Abstract/87888 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients
by: Taher, A.
Published: (2001) -
Febrile Neutropenia and Hemorrhagic Stroke in a Thalassemia Major Patient
by: Sheikh-Taha, Marwan
Published: (2007) -
Prevalence of Depression and Anxiety in Adult Patients with β-Thalassemia Major and Intermedia
by: Khoury, Brigitte
Published: (2012) -
Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
by: Mohamed A. Yassin (16322749)
Published: (2020) -
Spinal cord compression due to extramedullary hematopoiesis in patient with Beta thalassemia major
by: Eihab A. Subahi (12217761)
Published: (2023)